Posts Archive

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug...

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...

The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of...

NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...

PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...

NUTRIVENTION Study NCT04920084: A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or...

CAEL-101 Amy NCT04512235: Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL...

IMPACT STUDY The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study The Immune Profiling with Antibody-based COVID-19...

The clonoSEQ® Watch Registry Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The...

NCT04504825: Phase 3: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis...

(ITHACA) High-risk Smoldering Multiple Myeloma NCT04270409 NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and...

IFM 2017-04 - CARRISMM NCT04144387: Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New...

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...

DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...

NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma Denosumab for Smoldering Multiple Myeloma This study will assess the...

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy MGUS Rifaximin in Patients With Monoclonal Gammopathy This trial...

PROMISE NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population The PROMISE Study aims to...